Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2023-09-11 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于分公司获得《药品生产许可证》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding its branch receiving a 'Drug Production License' issued by the Heilongjiang Provincial Drug Administration. It details the license content, the impact on the company, and risk warnings. The document is short (721 characters) and is an announcement of a regulatory approval/license rather than a financial report or detailed management information. It does not contain financial data, earnings, or management changes. It is a regulatory announcement about a license acquisition, which fits best under Regulatory Filings (RNS).
2023-09-11 Chinese
哈药集团股份有限公司2023年半年度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled '2023 年半年度报告' which translates to '2023 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company information, and operational review for the period January 1 to June 30, 2023. The document is comprehensive, with over 15,000 characters, and includes financial statements and substantive financial data. It is not a brief announcement or a certification letter. The content matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year, containing actual financial statements and analysis. Therefore, the correct classification is IR with high confidence. H1 2023
2023-08-24 Chinese
哈药集团股份有限公司关于计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of 哈药集团股份有限公司 regarding the provision for asset impairment for the first half of 2023. It details the accounting policies and amounts related to bad debt, inventory write-downs, and fixed asset impairment provisions. The document includes opinions from the board, independent directors, and the supervisory board, confirming the appropriateness and compliance of the impairment provisions. The document length is 1888 characters, which is relatively short and primarily serves as an announcement of the impairment provision decision rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It is also not a certification or regulatory compliance filing. Therefore, this document fits best as a Regulatory Filing (RNS) because it is a formal announcement of an accounting decision and related disclosures that do not constitute a full report or other specific filing types.
2023-08-24 Chinese
哈药集团股份有限公司关于召开2023年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a 2023 half-year performance explanation meeting (业绩说明会) by 哈药集团股份有限公司. It mentions the date, time, location, and format of the meeting, as well as how investors can participate and ask questions. It references the 2023 half-year report already published on August 24, 2023, but this document itself is not the report or the transcript of the meeting. It is a notice about the upcoming investor presentation event related to the half-year results. The document length is short (1407 characters) and it does not contain financial data or detailed analysis, only information about the meeting. Therefore, it fits best as an Investor Presentation (IP) announcement or notice rather than the actual report or transcript. Given the content and context, the classification is Investor Presentation (IP) with high confidence.
2023-08-24 Chinese
哈药集团股份有限公司九届二十次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the supervisory board's resolution regarding the company's 2023 half-year report and asset impairment provisions. It includes the supervisory board's review and approval of the half-year report, confirming compliance with laws and regulations, but does not contain the actual financial statements or detailed financial data itself. The document is relatively short (710 characters) and serves as an official announcement of the supervisory board's approval rather than the report itself. Therefore, it fits best as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2023-08-24 Chinese
哈药集团股份有限公司九届三十八次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from 哈药集团股份有限公司 regarding the approval of the 2023 half-year report and asset impairment provisions. It mentions the board meeting date, voting results, and references the full half-year report being disclosed on the stock exchange website. The document itself does not contain the full financial statements or detailed financial analysis but rather announces the board's decisions and points to the full report elsewhere. The document length is short (778 characters) and serves as an announcement of board decisions and report publication rather than the report itself. Therefore, it fits best under Board/Management Information (MANG) as it details board resolutions and decisions, including approval of financial matters, rather than being the full interim report (IR) or a report publication announcement (RPA) since it contains substantive board decision content.
2023-08-24 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.